Article Text

Download PDFPDF

Response to: ‘Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey’ by Plüß et al
Free
  1. Alexis Mathian,
  2. Zahir Amoura
  1. Sorbonne Université, Assistance Publique–Hôpitaux de Paris, Groupement Hospitalier Pitié–Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
  1. Correspondence to Dr Alexis Mathian, Internal Medicine, University Hospital Pitié Salpêtrière, Paris 75651, France; alexis.mathian{at}psl.aphp.fr

Statistics from Altmetric.com

We thank Plüß et al for their interest in our study reporting on the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) in a case series of patients with systemic lupus erythematosus (SLE) under long-term treatment with hydroxychloroquine (HCQ).1 2 Plüß et al highlight a major point with respect to the consequences of the SARS-CoV2 outbreak on patients with SLE, in particular the difficulties that the latter have experienced in securing HCQ supplies for a licensed indication as a consequence of the off-label use of this drug to treat COVID-19 in the general population.

Plüß et al report that 70% of patients with SLE in Germany expressed concerns regarding the inability to receive their prescriptions for HCQ which was furthermore underscored by the observation that 46% also reported HCQ …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles